TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IIIb, 24-week, Randomised, Placebo-controlled, Double-blinded, Efficacy and Safety Study of Linagliptin (BI 1356) in Black/African American Patients With Type 2 Diabetes With a MTT Sub-study
Brief Summary: Study of linagliptin vs. placebo in Black/African American patients with T2DM with a MTT sub-study


Options:
A: Arm Label: Linagliptin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Linagliptin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Linagliptin; Assigned to Arm(s): Linagliptin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Drug: CIIIT | Intervention Type: DRUG; Name: CIIIT; Assigned to Arm(s): Treatment
C: Arm Label: Linagliptin; Type: EXPERIMENTAL; Interventions: Drug: Linagliptin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Linagliptin; Assigned to Arm(s): Linagliptin
D: Arm Label: Glycemia Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: Glycemia Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: BP Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hypertensive Agents | Arm Label: BP Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hypertensive Agents | Arm Label: Lipid Trial: fenofibrate; Type: EXPERIMENTAL; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Arm Label: Lipid Trial: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Intervention Type: DRUG; Name: Anti-hyperglycemic Agents; Assigned to Arm(s): Glycemia Trial: intensive control, Glycemia Trial: standard control | Intervention Type: DRUG; Name: Anti-hypertensive Agents; Assigned to Arm(s): BP Trial: intensive control, BP Trial: standard control | Intervention Type: DRUG; Name: Blinded fenofibrate or placebo plus simvastatin; Assigned to Arm(s): Lipid Trial: fenofibrate, Lipid Trial: placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic Syndrome
Brief Summary: The record Primary purpose is to assess the efficacy of eculizumab in adult patients with Atypical Hemolytic- Uremic Syndrome (aHUS) to control Thrombotic Microangiopathy (TMA) as characterized by thrombocytopenia, hemolysis and renal impairment.


Options:
A: Arm Label: Ravulizumab; Type: EXPERIMENTAL; Interventions: Biological: Ravulizumab | Intervention Type: BIOLOGICAL; Name: Ravulizumab; Assigned to Arm(s): Ravulizumab
B: Arm Label: Ravulizumab; Type: EXPERIMENTAL; Interventions: Biological: Ravulizumab | Intervention Type: BIOLOGICAL; Name: Ravulizumab; Assigned to Arm(s): Ravulizumab
C: Arm Label: Eculizumab; Type: EXPERIMENTAL; Interventions: Drug: Eculizumab | Intervention Type: DRUG; Name: Eculizumab; Assigned to Arm(s): Eculizumab
D: Arm Label: OMS721; Type: EXPERIMENTAL; Interventions: Biological: OMS721 | Intervention Type: BIOLOGICAL; Name: OMS721; Assigned to Arm(s): OMS721

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Low Intensity Pulmonary Outpatient Rehabilitation in Moderate to Severe COPD
Brief Summary: This randomised-controlled study is undertaken to investigate the effects of a long term low intensity outpatient training program on physical fitness and quality of life in moderate to severe COPD patients.


Options:
A: Intervention Type: BEHAVIORAL; Name: education; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Oral dietary supplements (563 kcal/d), RESPIFOR; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: exercises on an ergometric bicycle 3 to 5 times a week; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: 160 mg/d of oral testosterone undecanoate in men, 80 mg/d in women; Assigned to Arm(s): N/A
B: Arm Label: Intercom; Type: EXPERIMENTAL; Interventions: Other: INTERdisciplinary COMmunity-based COPD management (INTERCOM) | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: INTERdisciplinary COMmunity-based COPD management (INTERCOM); Assigned to Arm(s): Intercom
C: Intervention Type: BEHAVIORAL; Name: Intermediate care package; Assigned to Arm(s): N/A
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: pulmonary outpatient rehabilitation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: pulmonary outpatient rehabilitation | Intervention Type: PROCEDURE; Name: pulmonary outpatient rehabilitation; Assigned to Arm(s): pulmonary outpatient rehabilitation

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Low Intensity Pulmonary Outpatient Rehabilitation in Moderate to Severe COPD
Brief Summary: This randomised-controlled study is undertaken to investigate the effects of a long term low intensity outpatient training program on physical fitness and quality of life in moderate to severe COPD patients.


Options:
A: Arm Label: Remote-Monitoring Program; Type: EXPERIMENTAL; Interventions: Device: Cloud Dx Kit with remote-monitoring | Arm Label: Self-Monitoring Program; Type: EXPERIMENTAL; Interventions: Device: Cloud Dx Kit with self-monitoring | Arm Label: Standard of Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Cloud Dx Kit with self-monitoring; Assigned to Arm(s): Self-Monitoring Program | Intervention Type: DEVICE; Name: Cloud Dx Kit with remote-monitoring; Assigned to Arm(s): Remote-Monitoring Program
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: pulmonary outpatient rehabilitation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: pulmonary outpatient rehabilitation | Intervention Type: PROCEDURE; Name: pulmonary outpatient rehabilitation; Assigned to Arm(s): pulmonary outpatient rehabilitation
C: Arm Label: Intervention group "tele-rehabilitation"; Type: EXPERIMENTAL; Interventions: Behavioral: Virtual Autonomous Physiotherapist Agent (VAPA) | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Virtual Autonomous Physiotherapist Agent (VAPA) | Intervention Type: BEHAVIORAL; Name: Virtual Autonomous Physiotherapist Agent (VAPA); Assigned to Arm(s): Control, Intervention group "tele-rehabilitation"
D: Arm Label: Telemedicine; Type: ACTIVE_COMPARATOR; Interventions: Device: Telemedicine | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Telemedicine; Assigned to Arm(s): Telemedicine

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of an Electronic Nicotine Delivery Device (ENDD) on Smoking Cessation and Reduction: a Pilot Study
Brief Summary: The study's major aim is to investigate the ability of a commercial Electronic Nicotine Delivery Device (ENDD) to induce long-term smoking reduction/abstinence in smokers unwilling to quit. Secondary aims are to monitor adverse events and measure participants' perception and acceptance of the product.

This pilot study will evaluate smoking reduction/abstinence effects, product preferences, and adverse events of a currently marketed device in Italy ("Categoria" electronic cigarette - "ORIGINAL" 7.2 mg nicotine cartridges). The primary hypothesis is that the E-Cigarette is a safe device that allows smoking reduction or abstinence in smokers.


Options:
A: Arm Label: A; Type: PLACEBO_COMPARATOR; Interventions: Drug: nicotine versus placebo | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: nicotine versus placebo | Intervention Type: DRUG; Name: nicotine versus placebo; Assigned to Arm(s): A, B
B: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
C: Arm Label: E-Cigarette 7.2 mg nicotine; Type: EXPERIMENTAL; Interventions: Device: E-Cigarette 7.2 mg nicotine | Intervention Type: DEVICE; Name: E-Cigarette 7.2 mg nicotine; Assigned to Arm(s): E-Cigarette 7.2 mg nicotine
D: Arm Label: Nicotrol Inhaler; Type: EXPERIMENTAL; Interventions: Drug: Nicotrol Inhaler | Arm Label: Placebo Inhaler; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Inhaler | Intervention Type: DRUG; Name: Nicotrol Inhaler; Assigned to Arm(s): Nicotrol Inhaler | Intervention Type: DRUG; Name: Placebo Inhaler; Assigned to Arm(s): Placebo Inhaler

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of an Electronic Nicotine Delivery Device (ENDD) on Smoking Cessation and Reduction: a Pilot Study
Brief Summary: The study's major aim is to investigate the ability of a commercial Electronic Nicotine Delivery Device (ENDD) to induce long-term smoking reduction/abstinence in smokers unwilling to quit. Secondary aims are to monitor adverse events and measure participants' perception and acceptance of the product.

This pilot study will evaluate smoking reduction/abstinence effects, product preferences, and adverse events of a currently marketed device in Italy ("Categoria" electronic cigarette - "ORIGINAL" 7.2 mg nicotine cartridges). The primary hypothesis is that the E-Cigarette is a safe device that allows smoking reduction or abstinence in smokers.


Options:
A: Arm Label: EGO/CE4, 9mg nicotine; Type: OTHER; Interventions: Device: EGO/CE4, 9mg nicotine | Intervention Type: DEVICE; Name: EGO/CE4, 9mg nicotine; Assigned to Arm(s): EGO/CE4, 9mg nicotine
B: Arm Label: E-Cigarette 7.2 mg nicotine; Type: EXPERIMENTAL; Interventions: Device: E-Cigarette 7.2 mg nicotine | Intervention Type: DEVICE; Name: E-Cigarette 7.2 mg nicotine; Assigned to Arm(s): E-Cigarette 7.2 mg nicotine
C: Arm Label: Electronic cigarette condition; Type: EXPERIMENTAL; Interventions: Drug: Electronic cigarette with nicotine (ECwN) plus placebo tablets of varenicline | Arm Label: Varenicline condition; Type: ACTIVE_COMPARATOR; Interventions: Drug: Electronic cigarette without nicotine (ECwN) plus active varenicline tablets | Arm Label: Placebo condition; Type: PLACEBO_COMPARATOR; Interventions: Drug: Electronic cigarette without nicotine (ECwoN) plus placebo tablets of varenicline | Intervention Type: DRUG; Name: Electronic cigarette without nicotine (ECwN) plus active varenicline tablets; Assigned to Arm(s): Varenicline condition | Intervention Type: DRUG; Name: Electronic cigarette without nicotine (ECwoN) plus placebo tablets of varenicline; Assigned to Arm(s): Placebo condition | Intervention Type: DRUG; Name: Electronic cigarette with nicotine (ECwN) plus placebo tablets of varenicline; Assigned to Arm(s): Electronic cigarette condition
D: Arm Label: Nicotine; Type: EXPERIMENTAL; Interventions: Behavioral: Smoking cessation program TFC and activity tracker | Arm Label: Nicotine-free; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Smoking cessation program TFC-free and activity tracker | Arm Label: No-cig; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Smoking cessation program and activity tracker | Intervention Type: BEHAVIORAL; Name: Smoking cessation program TFC and activity tracker; Assigned to Arm(s): Nicotine | Intervention Type: BEHAVIORAL; Name: Smoking cessation program TFC-free and activity tracker; Assigned to Arm(s): Nicotine-free | Intervention Type: BEHAVIORAL; Name: Smoking cessation program and activity tracker; Assigned to Arm(s): No-cig

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of an Electronic Nicotine Delivery Device (ENDD) on Smoking Cessation and Reduction: a Pilot Study
Brief Summary: The study's major aim is to investigate the ability of a commercial Electronic Nicotine Delivery Device (ENDD) to induce long-term smoking reduction/abstinence in smokers unwilling to quit. Secondary aims are to monitor adverse events and measure participants' perception and acceptance of the product.

This pilot study will evaluate smoking reduction/abstinence effects, product preferences, and adverse events of a currently marketed device in Italy ("Categoria" electronic cigarette - "ORIGINAL" 7.2 mg nicotine cartridges). The primary hypothesis is that the E-Cigarette is a safe device that allows smoking reduction or abstinence in smokers.


Options:
A: Arm Label: Varenicline and Placebo Patch; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline and Placebo Patch | Arm Label: Varenicline and Nicotine Patch; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Nicotine Patch | Intervention Type: DRUG; Name: Varenicline, Nicotine Patch; Assigned to Arm(s): Varenicline and Nicotine Patch | Intervention Type: DRUG; Name: Varenicline and Placebo Patch; Assigned to Arm(s): Varenicline and Placebo Patch
B: Arm Label: E-Cigarette 7.2 mg nicotine; Type: EXPERIMENTAL; Interventions: Device: E-Cigarette 7.2 mg nicotine | Intervention Type: DEVICE; Name: E-Cigarette 7.2 mg nicotine; Assigned to Arm(s): E-Cigarette 7.2 mg nicotine
C: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: EGO/CE4, 9mg nicotine; Type: OTHER; Interventions: Device: EGO/CE4, 9mg nicotine | Intervention Type: DEVICE; Name: EGO/CE4, 9mg nicotine; Assigned to Arm(s): EGO/CE4, 9mg nicotine

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of an Electronic Nicotine Delivery Device (ENDD) on Smoking Cessation and Reduction: a Pilot Study
Brief Summary: The study's major aim is to investigate the ability of a commercial Electronic Nicotine Delivery Device (ENDD) to induce long-term smoking reduction/abstinence in smokers unwilling to quit. Secondary aims are to monitor adverse events and measure participants' perception and acceptance of the product.

This pilot study will evaluate smoking reduction/abstinence effects, product preferences, and adverse events of a currently marketed device in Italy ("Categoria" electronic cigarette - "ORIGINAL" 7.2 mg nicotine cartridges). The primary hypothesis is that the E-Cigarette is a safe device that allows smoking reduction or abstinence in smokers.


Options:
A: Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care | Arm Label: Brief Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Brief Intervention | Arm Label: Extended Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Extended Treatment | Intervention Type: BEHAVIORAL; Name: Brief Intervention; Assigned to Arm(s): Brief Treatment | Intervention Type: BEHAVIORAL; Name: Extended Treatment; Assigned to Arm(s): Extended Treatment | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): Usual Care
B: Arm Label: HIGH NICOTINE; Type: N/A; Interventions: N/A
C: Arm Label: E-cigarettes only; Type: N/A; Interventions: N/A | Arm Label: Traditional cigarettes only; Type: N/A; Interventions: N/A | Arm Label: Mixed group; Type: N/A; Interventions: N/A
D: Arm Label: E-Cigarette 7.2 mg nicotine; Type: EXPERIMENTAL; Interventions: Device: E-Cigarette 7.2 mg nicotine | Intervention Type: DEVICE; Name: E-Cigarette 7.2 mg nicotine; Assigned to Arm(s): E-Cigarette 7.2 mg nicotine

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of an Electronic Nicotine Delivery Device (ENDD) on Smoking Cessation and Reduction: a Pilot Study
Brief Summary: The study's major aim is to investigate the ability of a commercial Electronic Nicotine Delivery Device (ENDD) to induce long-term smoking reduction/abstinence in smokers unwilling to quit. Secondary aims are to monitor adverse events and measure participants' perception and acceptance of the product.

This pilot study will evaluate smoking reduction/abstinence effects, product preferences, and adverse events of a currently marketed device in Italy ("Categoria" electronic cigarette - "ORIGINAL" 7.2 mg nicotine cartridges). The primary hypothesis is that the E-Cigarette is a safe device that allows smoking reduction or abstinence in smokers.


Options:
A: Arm Label: Ecig 24 mg nicotine; Type: EXPERIMENTAL; Interventions: Device: Ecig 24 mg nicotine | Arm Label: Ecig 0 mg nicotine; Type: SHAM_COMPARATOR; Interventions: Device: Ecig 0 mg nicotine | Arm Label: Nicotine free inhalator; Type: PLACEBO_COMPARATOR; Interventions: Device: Nicotine free inhalator | Intervention Type: DEVICE; Name: Ecig 24 mg nicotine; Assigned to Arm(s): Ecig 24 mg nicotine | Intervention Type: DEVICE; Name: Ecig 0 mg nicotine; Assigned to Arm(s): Ecig 0 mg nicotine | Intervention Type: DEVICE; Name: Nicotine free inhalator; Assigned to Arm(s): Nicotine free inhalator
B: Arm Label: EGO/CE4, 9mg nicotine; Type: OTHER; Interventions: Device: EGO/CE4, 9mg nicotine | Intervention Type: DEVICE; Name: EGO/CE4, 9mg nicotine; Assigned to Arm(s): EGO/CE4, 9mg nicotine
C: Arm Label: cigarette substitute; Type: EXPERIMENTAL; Interventions: Other: cigarette substitute | Arm Label: e-cigarette (with 0 mg/ml nicotine); Type: EXPERIMENTAL; Interventions: Other: e-cigarette | Arm Label: e-cigarette (with 8 mg/ml nicotine); Type: EXPERIMENTAL; Interventions: Other: e-cigarette | Arm Label: e-cigarette (with 36 mg/ml nicotine); Type: EXPERIMENTAL; Interventions: Other: e-cigarette | Intervention Type: OTHER; Name: e-cigarette; Assigned to Arm(s): e-cigarette (with 0 mg/ml nicotine), e-cigarette (with 36 mg/ml nicotine), e-cigarette (with 8 mg/ml nicotine) | Intervention Type: OTHER; Name: cigarette substitute; Assigned to Arm(s): cigarette substitute
D: Arm Label: E-Cigarette 7.2 mg nicotine; Type: EXPERIMENTAL; Interventions: Device: E-Cigarette 7.2 mg nicotine | Intervention Type: DEVICE; Name: E-Cigarette 7.2 mg nicotine; Assigned to Arm(s): E-Cigarette 7.2 mg nicotine

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Six Month Randomized Controlled Dietary Intervention Study of the New Nordic Diet vs Average Danish Diet in Adults (18-65y) Using the Shop Model for Optimal Dietary Adherence
Brief Summary: The objective is to investigate whether New Nordic Diet (NND) versus Average Danish Diet (ADD) in adults (18-65 y) with central obesity and components of the metabolic syndrome can improve body weight loss and risk markers of the metabolic syndrome, type 2 diabetes and cardiovascular diseases.


Options:
A: Arm Label: LGI; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Low glycemic index diet | Arm Label: HGI; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: High glycemic index diet | Arm Label: HB; Type: EXPERIMENTAL; Interventions: Other: Home-based exercise intervention | Arm Label: CONTROL; Type: ACTIVE_COMPARATOR; Interventions: Other: Non-exercisers | Intervention Type: DIETARY_SUPPLEMENT; Name: Low glycemic index diet; Assigned to Arm(s): LGI | Intervention Type: DIETARY_SUPPLEMENT; Name: High glycemic index diet; Assigned to Arm(s): HGI | Intervention Type: OTHER; Name: Home-based exercise intervention; Assigned to Arm(s): HB | Intervention Type: OTHER; Name: Non-exercisers; Assigned to Arm(s): CONTROL
B: Arm Label: Standard Behavioral Weight Loss Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard Behavioral Weight Loss Intervention | Arm Label: Enhanced Weight Loss Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced Weight Loss Intervention | Intervention Type: BEHAVIORAL; Name: Standard Behavioral Weight Loss Intervention; Assigned to Arm(s): Standard Behavioral Weight Loss Intervention | Intervention Type: BEHAVIORAL; Name: Enhanced Weight Loss Intervention; Assigned to Arm(s): Enhanced Weight Loss Intervention
C: Intervention Type: BEHAVIORAL; Name: Caloric Restriction (CR); Assigned to Arm(s): N/A
D: Arm Label: New Nordic Diet; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary intervention | Arm Label: Average Danish Diet; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary intervention | Intervention Type: BEHAVIORAL; Name: Dietary intervention; Assigned to Arm(s): Average Danish Diet, New Nordic Diet

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Six Month Randomized Controlled Dietary Intervention Study of the New Nordic Diet vs Average Danish Diet in Adults (18-65y) Using the Shop Model for Optimal Dietary Adherence
Brief Summary: The objective is to investigate whether New Nordic Diet (NND) versus Average Danish Diet (ADD) in adults (18-65 y) with central obesity and components of the metabolic syndrome can improve body weight loss and risk markers of the metabolic syndrome, type 2 diabetes and cardiovascular diseases.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Diet with increased intake of rye bread, berries and fish | Arm Label: B; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Increased intake of whole grain and rye bread | Arm Label: C; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Control diet with decreased intake of rye bread, berries and fish | Intervention Type: DIETARY_SUPPLEMENT; Name: Diet with increased intake of rye bread, berries and fish; Assigned to Arm(s): A | Intervention Type: DIETARY_SUPPLEMENT; Name: Increased intake of whole grain and rye bread; Assigned to Arm(s): B | Intervention Type: DIETARY_SUPPLEMENT; Name: Control diet with decreased intake of rye bread, berries and fish; Assigned to Arm(s): C
B: Arm Label: DASH diet; Type: EXPERIMENTAL; Interventions: Behavioral: DASH diet | Arm Label: DASH diet plus Weight loss; Type: EXPERIMENTAL; Interventions: Behavioral: DASH diet plus Weight loss | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: DASH diet; Assigned to Arm(s): DASH diet | Intervention Type: BEHAVIORAL; Name: DASH diet plus Weight loss; Assigned to Arm(s): DASH diet plus Weight loss
C: Arm Label: New Nordic Diet; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary intervention | Arm Label: Average Danish Diet; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary intervention | Intervention Type: BEHAVIORAL; Name: Dietary intervention; Assigned to Arm(s): Average Danish Diet, New Nordic Diet
D: Arm Label: Low Fat Diet; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Low Fat Diet | Arm Label: Mediterranean Diet; Type: EXPERIMENTAL; Interventions: Behavioral: Mediterranean Diet | Intervention Type: BEHAVIORAL; Name: Mediterranean Diet; Assigned to Arm(s): Mediterranean Diet | Intervention Type: BEHAVIORAL; Name: Low Fat Diet; Assigned to Arm(s): Low Fat Diet

Answer: C